Stock Market Analysis Highlighting Eli Lilly's Performance
In a recent development, Eli Lilly's Orforglipron, a revolutionary weight loss tablet, is making waves in the pharmaceutical industry. The tablet, which could potentially break the expensive injectable monopoly of GLP-1 medications, is currently in the approval process.
Eli Lilly has completed successful Phase 3 studies by August 2025 and has prepared the full clinical package to apply for approval. The US FDA, with its new expedited review process introduced in July, is expected to accelerate the approval process, potentially granting approval within one to two months. However, it's important to note that no official approvals have yet been reported in other countries.
The market potential for Orforglipron is estimated to be $10 billion annually. Despite this promising figure, Eli Lilly is hesitant to use the FDA's new expedited approval process for Orforglipron, despite analyst predictions of billions in sales.
The latest Eli Lilly figures are being analysed for investment advice, with a focus on whether shareholders should buy or sell. A new analysis from September 17th provides advice on whether to buy or sell Eli Lilly stock.
The performance of Orforglipron in weight loss trials has dampened the enthusiasm of some analysts and investors. Recent Phase-3 results published in the New England Journal of Medicine show that Orforglipron achieved only 9% weight loss compared to placebo after 72 weeks. This result is significantly less than the 12-13% of competing drugs semaglutide.
However, analysts seem to consider the weaker performance of Orforglipron as manageable. Cantor Fitzgerald maintains its price target of $825 and reaffirms its overweight rating for Eli Lilly stock.
Orforglipron tablets are easier to produce than current injections, as they don't require a cold chain. This could potentially make the drug more accessible to a wider audience. Lilly plans to pursue approval for Orforglipron in multiple markets simultaneously, including the US, UK, EU, Japan, and China. Applications for Orforglipron's approval will be submitted within a few weeks.
Patrik Jonsson, President of Lilly International, stated that it's too early to assume they'll use the priority voucher for Orforglipron. The priority voucher, if used, would reduce the review time for the drug by several months.
The decision of whether investors should sell or buy Eli Lilly stocks due to Orforglipron's performance is a matter of debate among analysts. Some argue that the lower weight loss results could limit the drug's market potential, while others believe that the convenience and accessibility of the tablet form could outweigh this factor.
As we await the official approvals, the debate among analysts continues. The potential of Orforglipron as a game-changer in the weight loss drug market is undeniable, and investors will be closely watching its progress.
Read also:
- Competing strategies for addressing infertility come under scrutiny in the halls of Congress
- High school football in Ohio called off due to a legal dispute claiming players suffered violent hazing incidents
- Job opening at Save the Children organization
- Essential Techniques for Successful Snack Food Business Branding
